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Abstract 11 
Cutaneous leishmaniasis (CL) is caused by several species of the protozoan parasite Leishmania and 12 
affects approximately 10 million people worldwide. Currently available drugs are not ideal due to high 13 
cost, toxicity, parenteral administration and suboptimal efficacy.  Miltefosine is the only oral 14 
treatment (Impavido®) available to treat CL, given over a period of 28 days with common side effects 15 
such as vomiting and diarrhoea.  16 
Objective. To explore the local application of miltefosine as a topical formulation to enhance activity 17 
and reduce the drug’s adverse effects.  18 
Methods. The anti-leishmanial activity of miltefosine was confirmed in vitro against several Leishmania 19 
species. The permeation of miltefosine, in different solvents and solvent combinations, through 20 
BALB/c mouse skin was evaluated in vitro using Franz diffusion cells. The topical formulations which 21 
enabled the highest drug permeation or skin disposition were tested in vivo in BALB/c mice infected 22 
with L. major.  23 
Results. The overall permeation of miltefosine through skin was low regardless of the solvents used. 24 
This was reflected in limited anti-leishmanial activity of the drug formulations when applied topically 25 
in vivo. All topical formulations caused skin irritation. 26 
Conclusions.  We conclude that miltefosine is not an appropriate candidate for the topical treatment 27 
of CL. 28 
Keywords: miltefosine, cutaneous leishmaniasis, topical formulation, drug delivery, skin. 29 
  
Introduction 30 
The leishmaniases are poverty-related diseases caused by up to 20 Leishmania species [1] that are 31 
transmitted by  sandflies. With 220 000 new cases a year, cutaneous leishmaniasis (CL) is the most 32 
common form of leishmaniasis [2]. The presence of the Leishmania parasites in macrophages in the 33 
skin dermis causes a range of clinical symptoms, from small nodules to large plaques and disfiguring 34 
ulcers. Drugs currently administered to treat CL are mainly repurposed  with sub-optimal efficacy 35 
attributable to (i) differences in drug susceptibility between the different Leishmania species which 36 
can lead to sub-therapeutic drug concentrations [3, 4], (ii) the failure of the drug to reach the target 37 
tissue, (iii) adverse effects [5] and being not patient-friendly [6]. Currently there is no safe treatment 38 
that is guaranteed to cure CL. 39 
Miltefosine (Figure 1) is an anti-leishmanial drug that is used as an oral formulation for the treatment 40 
of visceral leishmaniasis (VL) [7, 8] and  in several countries to treat CL [9]. The most frequently 41 
reported side effects are (i) gastro-intestinal discomfort that is often the cause of poor compliance to 42 
therapy [10], (ii) teratogenicity that calls for adequate contraception throughout the treatment of 43 
young females, and (iii) hepato- and nephrotoxicity requiring patient monitoring [11]. A topical 44 
miltefosine treatment would offer certain advantages over systemic treatment. The formulation, 45 
directly applied to the target site, would avoid or at least reduce potential side effects of systemic 46 
exposure, require less intensive patient follow up and would also improve patient compliance. As 47 
miltefosine is already approved for clinical use, reformulating miltefosine into a topical treatment 48 
could provide a more cost effective route for treatment development compared to a ‘de novo’ drug 49 
discovery process especially in an area with minimal financial incentive.   50 
To permeate the stratum corneum, the main barrier to permeation for most topically applied drugs, 51 
an active compound should ideally have a low molecular weight (< 500 g/mol) [12], less than three H- 52 
bond donors [13], good solubility in the formulation vehicle and a partition coefficient between one 53 
and three [14, 15]. The physico-chemical properties of miltefosine (Figure 1), are indicative of 54 
potential skin permeation. Moreover, recent studies have shown enhanced permeation of drugs, 55 
particularly drugs with high water solubility, through Leishmania-infected mouse skin [16] and a 56 
topical miltefosine solution (Miltex®) has been used to treat superficial metastases of skin cancer, 57 
indicating some drug permeation. . However, miltefosine is an amphiphilic and zwitterionic molecule 58 
at skin pH (pH 5.5) containing both a positive and a negative charge (pKa ≈ 2) [17] and behaves as a 59 
surfactant. The inherent aqueous solubility of such compounds challenges permeation through 60 
lipophilic membranes such as stratum corneum.   61 
  
Our aim therefore was to systematically investigate, for the first time, the potential of miltefosine as 62 
a topical anti-leishmanial drug. We evaluated (i) the activity of miltefosine against a range of 63 
intracellular Leishmania amastigotes in vitro, (ii) the permeation of miltefosine when applied to 64 
BALB/c mouse skin in a range of solvents (propylene glycol (PG), water, dimethyl isosorbide (DMI) and 65 
octyl salicylate (OSAL)) using Franz diffusion cells, (iii) the potential  enhancement of in vitro 66 
permeation using a combination of these solvents  and (iv) the in vivo anti-leishmanial activity of the 67 
optimal solvent systems upon topical administration in BALB/c mice. The solvents were chosen 68 
because (i) they had a broad range of physicochemical properties, (ii) they have been reported to 69 
enhance percutaneous drug delivery (Table 1), and (iii) they have  been approved by the FDA as 70 
inactive ingredient for drug products [18].  71 
Materials and Methods 72 
Materials 73 
Miltefosine was donated by Paladin Labs Inc (Montréal, Canada). The [14C]-miltefosine (specific 74 
activity: 36mCi/mmol, concentration: 900uCi/ml, radiochemical purity: 98.3%) was from Nycomed 75 
Amersham Pharmacia (Buckinghamshire, UK). Schneider’s insect medium, RPMI-1640 and M199 76 
medium were obtained from Sigma Aldrich (Dorset, UK). Foetal calf serum was from Harlan 77 
Laboratories (Derbyshire, UK) and heat-inactivated by exposure  to 56°C for 30 minutes. 78 
Propylene glycol (PG), dimethyl isosorbide ether (DMI), octyl salicylate (OSAL) and phosphate buffered 79 
saline (PBS) tablets were from Sigma Aldrich (UK). The Franz diffusion cells,  diameter of 0.90±0.03 cm 80 
and mean receptor volume of 2.65±0.06 ml, were obtained from Soham Scientific (Fordham, UK). The 81 
Optiphase™ supermix and Hionic Fluor™ liquid scintillation cocktails and Solvable™ were purchased 82 
from Perkin Elmer (Coventry, UK).  Liposomal amphotericin B (AmBisome®, Gilead Sciences, USA) and 83 
amphotericin B deoxycholate (Fungizone®, ER Squibb, UK) were reconstituted according to 84 
manufacturer’s instructions. 85 
Leishmania parasites, cell culture and animals 86 
Promastigotes of L. major (MHOM/SA/85/JISH118); L. panamensis (MHOM/PA/67/BOYNTON); L. 87 
aethiopica (MHOM/ET/84/KH); L. mexicana (MNYC/ BZ/62/M379) and L. tropica 88 
(MHOM/IR/2013/HTD4) were taken from liquid nitrogen stocks. L. panamensis was cultured in M199  89 
medium plus 10% heat-inactivated fetal calf serum (HiFCS) at 26°C while the other four species were 90 
cultured in Schneider’s  insect medium supplemented with 10% HiFCS.  91 
Female BALB/c mice (6-8 weeks old) were purchased from Charles River (Margate, UK) and housed in 92 
a controlled environment of 55% relative humidity and 26°C. They were provided with tap water and 93 
  
a standard laboratory diet. All animal experiments were approved by the Animal Welfare and Ethical 94 
Review Board of the London School of Hygiene & Tropical Medicine and carried out under UK home office 95 
licence (PPL 70/8207) according to the Animals (Scientific Procedures) Act 1986 and EU Directive 96 
2010/63/EU. 97 
Evaluation of the anti-leishmanial activity of miltefosine against intracellular amastigotes 98 
Peritoneal exudate macrophages (PEMs) were harvested by lavage 24 hours after starch induction (2% 99 
aq) from female CD-1 mice (LSHTM in house colony). The cells were seeded in 16-well Lab-Tek™ slides 100 
in RPMI-1640 supplemented with 10% HiFCS at a density of 4x104 per well (100 μl). After 24 hours 101 
incubation at 37°C and 5% CO2/95% air mixture, the adhered PEMs were infected with stationary 102 
phase promastigotes at a ratio of 3:1  (for L. tropica and L. major) or 5:1 (for L. mexicana, L. aethiopica 103 
and L. panamensis) promastigotes and maintained at 34°C in a 5% CO2/95% air mixture. 24 Hours later, 104 
the  infection was checked and the overlay replaced with medium-containing drug, in quadruplicate. 105 
Final miltefosine concentrations were 30, 10, 3 & 1 μM. Amphotericin B (Fungizone®) was included as 106 
control drug. After 72 hours incubation, all the slides were methanol-fixed and Giemsa-stained. Drug 107 
activity was determined microscopically by counting the number of infected macrophages in drug-108 
treated cultures compared to untreated cultures. The EC50 and EC90 values were calculated by non-109 
linear sigmoidal curve fitting (variable slope) using Prism Software (GraphPad, UK). 110 
Exploration of topical drug delivery systems for miltefosine 111 
Drug solubility. The saturated solubility of miltefosine in PG, DMI, OSAL and water was determined as 112 
described by [19]. Drug concentrations were determined by LC-MS (Finnigan LCQ, analytical 113 
laboratory, LSHTM).  114 
Solvent miscibility. In order to deliver the drug from a stable solvent system, the compatibility of 115 
solvents was explored in binary and ternary phase miscibility studies. The appropriate volume and 116 
ratio of solvents (v/v) were added into vials that were vortexed for two minutes and left to stand at 117 
room temperature. After one hour, the samples were marked as immiscible (when phase separation 118 
was visible) or miscible (when a homogeneous phase was seen). Ternary phase diagrams were drawn 119 
using the OriginPro software (Northampton, UK) 120 
Permeation and disposition of miltefosine in BALB/c mouse skin. The test formulations contained 6% 121 
(w/v) miltefosine (same as Miltex®) in the appropriate vehicle consisting of a single, binary or ternary 122 
solvent mixture. After addition of miltefosine, the mixture was stirred overnight at 32°C. Before 123 
application to the skin, the drug formulations were spiked with [14C]-miltefosine to a final 124 
concentration of 4 µCi/ml and vortexed for two minutes.  125 
  
On the day of the permeation experiment, the mice were sacrificed and full-thickness dorsal skin was 126 
removed, and cut to circular discs that were mounted between the donor and receptor compartments 127 
of the Franz diffusion cells. The receptor fluid, PBS (pH 7.4), was sonicated and placed into the receptor 128 
compartment together with a magnetic stirrer and the cells were incubated in a warm water bath 129 
(32°C). After one hour, 500 µl of the test solution was applied to each donor compartment after which 130 
200 µl of receptor phase was removed and replaced with fresh PBS at regular time intervals over a 131 
duration of 48 hours.  132 
For the quantification of miltefosine, 100 µl of the receptor sample was transferred to a 96-well 133 
flexible MicroBeta plate (Perkin Elmer, UK) and 100 µl of Optiphase™ supermix was added. A standard 134 
curve was prepared by double-diluting the donor solution in PBS for PG and water and in methanol 135 
for DMI and OSAL, as the latter two solvents are not miscible with water. Blanks consisted of 100 µl 136 
PBS or methanol and 100µl of Optiphase™ supermix. Scintillation counting was conducted using a 137 
Microbeta2 plate reader equipped with 2 detectors (Perkin Elmer, UK). The cumulative amount of 138 
drug permeated per surface area of skin was plotted as a function of time. The slope and thus flux was 139 
calculated by linear regression of the data points obtained between 20 and 36 hours following topical 140 
drug application.  141 
After 48 hours, the permeation experiment was terminated and mass balance studies were conducted 142 
as follows. The donor solution was transferred into a clean vial and any left overs were removed from 143 
the skin by carefully wiping the surface with a cotton swab, followed by repeatedly pipetting with one 144 
ml of a methanol:water (3:7 (v/v)) solution. This was repeated three times. To extract the miltefosine 145 
absorbed in the cotton, one ml of a methanol:water (3:7 (v/v)) solution was added to the vial 146 
containing the swab, and the mixture was left on a shaking plate for five hours, after which 100 μl of 147 
the liquid was transferred to a flexible Microbeta 24-well plate. To quantify the amount of miltefosine, 148 
400 μl of Hionic-fluor™ scintillation fluid was added and left to acclimatize before reading with a 149 
Microbeta2 plate reader. For each formulation tested, a standard curve of 12 serial double dilutions 150 
was included and each plate also contained three methanol:water blanks. The amount of miltefosine 151 
in each sample was calculated from the miltefosine standard curve.  152 
To determine the amount of miltefosine in the skin, the skin and one ml of Solvable™ were transferred 153 
to a vial, incubated at 50°C and vortexed regularly until a homogenous mixture was obtained. A sample 154 
of this homogenate (100 μl) was mixed with Hionic-fluor™ (300 μl) in a microbeta plate and analysed 155 
using the Microbeta2 plate reader. Controls (in triplicate) included untreated skin spiked with a known 156 
amount of radiolabelled miltefosine to confirm no drug breakdown occurred during the extraction 157 
  
procedure, and skin unexposed to any drug to correct for effects due to skin components. The amount 158 
of miltefosine in each sample was calculated using the miltefosine standard curve.  159 
 160 
In vivo evaluation of the anti-leishmanial activity of topical formulations  161 
60 Female BALB/c mice were subcutaneously injected with 2x107 stationary phase L. major JISH118 162 
promastigotes (200 μl) on the rump above the tail. Approximately seven days post infection, small 163 
nodules were visible. When the nodule reached a diameter of 3-4 mm, the mice were randomly 164 
allocated to nine groups of five mice to test the drug formulations, and five groups of three mice to 165 
test the effect of the solvent (without miltefosine).  166 
Five different formulations were chosen based on the outcome of the permeation and mass balance 167 
study. They were 6% (w/v) miltefosine in water, in PG, in OSAL, in DMI and in OSAL-DMI (1:1). For the 168 
groups receiving a topical formulation (or controls) 50 μl was applied to the lesion twice daily. One 169 
group received miltefosine (in water) orally at a dose equivalent to 20mg/kg once a day. AmBisome® 170 
(25 mg/kg) was administered intravenously every other day. Formulations were administered over a 171 
period of 5 days except for the groups receiving AmBisome® or miltefosine orally; these received 172 
treatment over a duration of 10 days.  173 
The efficacy of the formulation was evaluated by assessing (i) rate of change of lesion size and (ii) 174 
parasite load. The lesion diameter was measured daily in 2 perpendicular directions using digital 175 
callipers and the average diameter was plotted as a function of time. Three days after the end of drug 176 
administration, the parasite load was determined by counting the amastigotes microscopically after 177 
homogenisation of the whole lesion in 1ml of sterile PBS. 178 
Statistical analyses. The EC50 and EC90 values were calculated by non-linear sigmoidal curve fitting 179 
(variable slope) using Prism Software (GraphPad, UK). The results of the in vitro permeation and the 180 
in vivo parasite load post-treatment were evaluated for statistical differences using a one-way ANOVA 181 
post hoc Tukey test (SPSS software, version 19.0), while the lesion size progression among the groups 182 
was evaluated using repeated measures ANOVA. SPSS software, version 19.0 was used for all analyses 183 
and differences were considered statistically significant at p<0.05.  184 
Results 185 
In vitro anti-leishmanial activity of miltefosine 186 
Miltefosine exhibited variable activity against a panel of Leishmania parasites as shown in Table 2.  187 
EC50 and EC90 values ranged from 7.8 µM to 45.9 µM and 19.5 µM to 166.3 µM respectively. When 188 
ranking the activity, miltefosine was most active against L. aethiopica > L. tropica > L. panamensis > L. 189 
  
major > L. mexicana. Amphotericin B, included as control drug, was highly active (in the nanomolar 190 
range) against all species.  191 
Saturated solubility of miltefosine in the solvents and solvent miscibility 192 
Miltefosine was highly soluble in water and PG (at 440 and 738 mg/ml respectively), while its solubility 193 
in OSAL and DMI (at 36 and 5 µg/ml respectively) was approximately four to five orders of magnitude 194 
lower.  195 
Miscibility of binary and ternary solvent mixtures are shown in Table 3 and Figure 2 respectively. PG, 196 
water and DMI are miscible when combined in binary systems and hence the influence of 197 
combinations of these solvents on the permeation of miltefosine were tested in permeation studies. 198 
OSAL had limited miscibility with other solvents, being miscible with only DMI at a ratio of 1:1; this 199 
binary mixture was also evaluated in permeation studies. To ensure miscibility throughout the 200 
experiment, two ternary phase systems away from the miscible/immiscible boundary were selected. 201 
These included OSAL-DMI-PG (2:5:3) and H2O-DMI-PG (3:4:3). An OSAL-DMI-H2O mixture was not 202 
included due to limited miscibility. 203 
Influence of solvents on the In vitro permeation of miltefosine 204 
The permeation profiles of the formulations tested (Table 4) are shown in Figure 3. When the influence 205 
of single solvents on miltefosine permeation was analysed, it was seen that miltefosine did not 206 
permeate the skin when dissolved in PG, in contrast to permeation from water, DMI or OSAL. There 207 
was no statistically significant difference in flux when the drug was applied in water, DMI and OSAL 208 
(Table 5, p>0.05).  209 
Based on these initial findings, the influence of four miscible binary and two ternary solvent mixtures 210 
on miltefosine permeation through skin was tested. During the first 36 hours of permeation, 211 
miltefosine only permeated BALB/c mouse skin when applied in DMI-OSAL (1:1). There was no 212 
significant difference in flux when compared to the single solvent mixtures water, DMI and OSAL 213 
(Table 5, p>0.05). The lag time and permeability coefficient for this binary solvent formulation were, 214 
however, significantly lower compared to those of the single solvent formulations ( p<0.05).  215 
The mass balance studies showed that only a very small fraction of the applied drug (< 4%) had 216 
permeated through the skin from all formulations over 48 hours. Beyond 36 hours, an increase in 217 
permeation was seen for most formulations in particular for the miltefosine in water formulation. This 218 
was not unexpected as surfactants and particularly ionic surfactants such as miltefosine are known 219 
skin irritants and have been reported to damage the skin [20-23], which would result in enhanced 220 
  
permeation. Total drug recovery ranged from 76%-102% (Figure 4) with most of the applied drug 221 
remaining on the skin surface. Miltefosine could not be detected in the skin when applied in PG, H2O-222 
DMI, or the two ternary phase solvent systems. For the other six formulations, only small fractions of 223 
the applied miltefosine ranging from 0.5-1.4% were found in the skin, with no significant difference 224 
among the formulations tested (p<0.05).  225 
 226 
In vivo anti-leishmanial activity  227 
Four formulations that demonstrated skin permeation in vitro i.e. 6% miltefosine (w/v) in water, DMI, 228 
OSAL and DMI-OSAL (1:1), were tested in vivo against experimental CL. The lesion size in the 229 
experimental groups progressed at the same rate as the untreated control (Figure 5, p>0.05) indicating 230 
no in vivo efficacy of topical miltefosine. However, the topical application of both control and drug 231 
formulations was halted after five days due to skin irritation. In contrast, the positive control, 232 
intravenous AmBisome® reduced the size of the lesion significantly (p<0.05).  233 
When the parasite load in the lesions was compared (Figure 6), no clear trend emerged. Of the treated 234 
groups, mice receiving AmBisome® showed a statistically significantly lower parasite burden 235 
compared to the groups receiving oral miltefosine, topical miltefosine in OSAL, topical DMI only and 236 
OSAL only (p<0.05). No single group had a significantly lower parasite load than the untreated control 237 
(p>0.05).  238 
Discussion  239 
Miltefosine is a recommended oral treatment for both cutaneous and visceral leishmaniasis. We 240 
confirmed the in vitro activity of miltefosine against a panel of species that cause CL with similar 241 
activities to previously reported [24, 25]. Only the EC50 values for L. mexicana were higher, probably 242 
due to the different strain used. Overall miltefosine was slightly less active against L. mexicana and L. 243 
major, which was not unexpected as difference in intrinsic sensitivity to miltefosine across Leishmania 244 
species is known [3, 24].  245 
In vitro permeation assays showed limited permeation of miltefosine across full-thickness mouse skin 246 
even when applied in different solvents or solvent mixtures. This was not unexpected as the stratum 247 
corneum consists of dead cells surrounded by lipids, expecting to hinder the diffusion of hydrophilic 248 
molecules such as miltefosine. Moreover, Miltex®, a topical solution of 6% miltefosine (w/v) in 249 
propylene glycol ethers was indicated for cutaneous metastases of breast cancer with limited depth 250 
[26] possibly due to the ability of miltefosine to permeate into the superficial layers of the skin where 251 
  
the cancer cells are situated, while it is unable to reach the dermis where Leishmania amastigotes 252 
reside inside macrophages.  253 
Different solvents were used to enhance the permeation of miltefosine into the skin. Miltefosine 254 
demonstrated a higher saturated solubility in water and PG compared to DMI and OSAL. This is 255 
important as the saturation level of a drug in its formulation is positively related to the thermodynamic 256 
activity, the driving force for permeation [27, 28]. In fact, the permeation of miltefosine was slightly 257 
higher when applied in DMI or OSAL because these formulations were suspensions and consequently, 258 
the thermodynamic activity of the active compound in its vehicle, was maximal and equal to one. In 259 
contrast, no permeation was observed when miltefosine was applied in PG, the solvent in which 260 
miltefosine demonstrated the highest solubility. There was some permeation when miltefosine was 261 
applied in water, however, the high solubility of miltefosine in both solvents resulted in a lower 262 
thermodynamic activity and thus a lower permeation. Furthermore, the permeability coefficient (Kp) 263 
for the drug formulation in water was statistically significantly lower compared to Kp for the DMI and 264 
OSAL formulation. This indicated that miltefosine when formulated in water had a low affinity for the 265 
skin but a high affinity for the vehicle which was reflected by the high solubility of miltefosine in water. 266 
Moreover the high permeability coefficients for miltefosine in DMI and OSAL indicated a high affinity 267 
for the skin and favoured partitioning into the skin. Previous studies reported an enhanced 268 
percutaneous drug permeation when binary and even ternary miscible solvent systems were used 269 
compared to single solvents [29-34]. A combination of solvents, however, does not always result in an 270 
additional increase of drug permeation [35, 36]. Our results show no enhanced permeation of 271 
miltefosine when solvent mixtures were used. In fact, the flux obtained using the binary OSAL-DMI 272 
combination was 40 times lower than the flux obtained when using OSAL and DMI alone.  273 
The overall low permeation of miltefosine upon topical application is probably why the formulations 274 
were unable to cure CL in BALB/c mice as indicated by an increasing lesion size and a high parasite 275 
load. In contrast to our results, Schmidt-Ott et al reported that  Miltex®, which also contained 6% 276 
miltefosine, cured CL lesions due to L. major and L. mexicana upon topical application [37]. However, 277 
these results were not reproducible when conducted in our lab (Yardley and Croft, unpublished data), 278 
even though the activity of miltefosine against a range of Leishmania species was confirmed [24]. 279 
Two clinical trials were conducted to evaluate the efficacy of topical Miltex® against CL (Bachmann P., 280 
unpublished data). One trial was conducted in Syria and included 16 patients with nodular CL who 281 
applied the formulation twice daily. The other trial was conducted in Colombia where the 19 involved 282 
patients received treatment once a day for 4 weeks [38]. Both trials of topically applied Miltex® were 283 
  
unable to show efficacy against CL, even though oral administration has been shown to cure CL in 284 
patients [4, 39].   285 
In this study we observed that oral miltefosine (20mg/kg/day) was also unable to reduce the lesion 286 
size or the parasite burden in the skin of mice, confirming a previous  study that  showed no significant 287 
lesion size reduction with a similar dose of miltefosine  although higher doses, with toxic side effects,   288 
did reduce lesion size and parasite burden [40]. In contrast, in a clinical trial in Iran, oral miltefosine 289 
was shown to be effective against CL caused by L. major with cure rate of about 81% [41]. 290 
Additionally, we observed that the lesion size results did not correlate with the parasite load per 291 
lesion. A possible explanation could be (i) the skin irritation that exaggerated the lesion size readings 292 
by enhancing the lesion size and (ii) the large variation in parasite burdens observed per group.  293 
Moreover, severe skin irritation observed in the groups receiving miltefosine topically, required an 294 
early halt to dosing. This was not surprising as surfactants such as miltefosine have been reported to 295 
damage skin. Research has shown protein denaturation [20], swelling of the stratum corneum [21] 296 
and lipid depletion and solubilisation in the stratum corneum [22]. Additionally, OSAL was reported to 297 
be mildly irritating when applied to rabbit skin which could have caused further damage to the skin 298 
[42].  299 
It is unclear how our results would translate to disease in humans. First, there are physical differences 300 
between human and mouse skin for example full-thickness mouse [43]. Furthermore the number of 301 
hair follicles and differences in the composition of intercellular SC lipids [44] also contribute to the 302 
overall higher permeability of mouse skin compared to human skin [45-47]. 303 
Conclusion 304 
Although miltefosine showed activity against a panel of Leishmania parasites in vitro, this did not 305 
translate into in vivo activity when tested in topical formulations against experimental CL in mice. In 306 
vitro Franz diffusion cell studies showed poor drug permeation into and through the skin, suggesting 307 
that miltefosine probably did not reach the parasites that reside in the dermal layer of the skin. 308 
Moreover after 5 days of in vivo application, all treatments including the formulation that contained 309 
water as vehicle, had caused significant irritation and drug application had to be stopped. We conclude 310 
that miltefosine is not an appropriate candidate for topical treatment for CL. 311 
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Table 1.  The four selected solvents, dimethyl isosorbide, octyl salicylate, propylene glycol and water 455 
and their physicochemical properties.   456 





Mol. Wt. (g/mol) 174 250 76 18 
Log KO/W 0.07 5.97 -1.06 -1.38 
Solubility parameter 
(cal/cm3)1/2 
9.97 10.87 14.07 22.97 
Density at 25°C 
(g/cm3) 
1.16 1.1 1.04 1.0 
Penetration 
enhancement 
[48] [49-51] [52, 53] [54, 55] 
 457 
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Table 2.  In vitro anti-leishmanial activity as determined by microscopic counting of Leishmania 459 
infected macrophages treated with miltefosine (30, 10, 3.3 and 1.1 uM; n= number of experiments).  460 
Compound n 
Amphotericin B Miltefosine 
EC50 (µM) (95% CI) EC90 (µM) EC50 (µM) (95% CI) EC90 (µM) 
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Table 3. Miscibility of binary solvent mixtures (1:1 ratio,  miscible;  immiscible). 465 
 466 
 OSAL DMI water PG 
OSAL     
DMI     
water     
PG     
 467 
  468 
  
Table 4. The saturation level and thermodynamic activity of the test formulations containing 6% 469 
miltefosine (w/v). 470 
Formulations tested 
Saturated? Yes/no 
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Table 5. Skin permeation parameters of miltefosine and the influence of solvents (H2O, DMI, OSAL 473 
and DMI-OSAL (1:1)). Each value represents the average±SD (n=4).  474 
6% miltefosine in H2O DMI OSAL OSAL-DMI 
Permeation parameters 
Flux (µg/cm2/h) 
Lag time (h) 
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Figure 1. Chemical structure and physicochemical properties of miltefosine. 479 
 480 
Figure 2. Miscibility of ternary solvent mixtures. (black dots: miscible system; green dot: solvent 481 
system selected for in vitro permeation studies). 482 
 483 
Figure 3. In vitro permeation assay using full-thickness BALB/c mouse skin in Franz diffusion cells. 484 
The cumulative amount of miltefosine that permeated per skin area expressed as a function of time 485 
(average+SD, n=4).  486 
 487 
Figure 4. Skin disposition of miltefosine. Distribution of topically applied miltefosine formulations on 488 
the skin surface, extracted from the skin or that had permeated through the skin 48h after single-dose 489 
application. Data shown were obtained using full-thickness BALB/c mouse skin (average ±SD; n=4).  490 
 491 
Figure 5. In vivo anti-leishmanial activity – lesion size. The in vivo activity of five formulations 492 
containing 6% (w/v) miltefosine in the non-healing cutaneous lesion model in BALB/c mice infected 493 
with L. major promastigotes. Lesions were treated with 50ul of formulation topically applied once daily 494 
for five days. The graph shows the progression of the average lesion size diameter per group as a 495 
function of time (n=5 except for vehicle control groups where n=3, average±SD). The rate of lesion size 496 
progression in the group receiving AmBisome is statistically significantly different from the other 497 
treatment groups (p<0.05, repeated measures ANOVA). 498 
Figure 6. In vivo anti-leishmanial activity – parasite burden. The in vivo activity of five formulations 499 
containing 6% (w/v) miltefosine in the non-healing cutaneous lesion model in BALB/c mice infected 500 
with L. major promastigotes. Lesions were treated with 50ul of formulation topically applied once 501 
daily for five days. The graph shows the average parasite load per lesion per group two days after the 502 
last drug application (n=5 except for vehicle control groups where n=3, average±SD). The average 503 
parasite load in the marked groups (*) was statistically significant higher compared to the group 504 
receiving AmBisome (p < 0.05, One-Way ANOVA) 505 
